



Pelago Bioscience grants Pfizer Inc. license to the CETSA™ method

Tuesday, October 13, 2015 - 07:44am

Pelago Bioscience AB has entered into a commercial license agreement and technology collaboration with Pfizer Inc. Under the agreement, Pelago Bioscience grants Pfizer a license to use and apply the Cellular Thermal Shift Assay (CETSA™) for determination and quantification of drug-target interactions. Under the agreement, Pelago Bioscience and Pfizer may share information related to improvement in the use of the technology. Other Terms and Conditions associated with the Agreement have not been disclosed.

“We are very happy and excited that Pfizer has acquired a license to the CETSA method, a novel label-free technology for interrogating target engagement of small molecules in intact cells and tissue. We believe that Pfizer’s acquisition of a license is indeed a quality stamp and measure of the importance of the CETSA method in targeted drug discovery,” says Michael Dabrowski CEO of Pelago Bioscience. “We hope that the use of the CETSA method in Pfizer’s drug discovery research will further validate applications of the CETSA method in the development of novel pharmaceuticals.”

Mark Bunnage, Vice President, Worldwide Medicinal Chemistry at Pfizer commented: *“We believe that the CETSA method may hold promise within our research at Pfizer, and we look forward to working with our counterparts at Pelago.”*

About Pelago Bioscience AB

Spun out from the Karolinska Institute, Stockholm Sweden, Pelago Bioscience AB (<http://pelagobio.com>) was founded to provide and develop the patented Cellular Thermal Shift Assay (CETSA™) for use in determination and quantification of drug-target interactions. The company delivers in situ target engagement studies to accelerate preclinical and clinical drug discovery and diagnostics development. Using CETSA data

and applications, drug discovery R&D companies are able to make better and more informed decisions at earlier stages in their projects. This reduces time and money spent on the nonoptimal compounds and allows faster development of more efficacious new drugs.

For more information:

Pelago Bioscience AB

Michael Dabrowski, CEO, tel. +46 (0)730 715 334, michael@pelagobio.com